These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25278982)

  • 1. Effect of High Dose Rosuvastatin Loading before Percutaneous Coronary Intervention on Contrast-Induced Nephropathy.
    Yun KH; Lim JH; Hwang KB; Woo SH; Jeong JW; Kim YC; Joe DY; Ko JS; Rhee SJ; Lee EM; Oh SK
    Korean Circ J; 2014 Sep; 44(5):301-6. PubMed ID: 25278982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome).
    Leoncini M; Toso A; Maioli M; Tropeano F; Villani S; Bellandi F
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):71-9. PubMed ID: 24076283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials.
    Liang M; Yang S; Fu N
    Medicine (Baltimore); 2017 Jul; 96(27):e7384. PubMed ID: 28682890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
    Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Chronic Statin Therapy on Postprocedural Contrast-Induced Nephropathy in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention.
    Chanin JM; Yang DC; Haider MA; Swaminathan RV; Kim LK; Charitakis K; Tanoue M; Minutello RM; Gade CL; Singh HS; Bergman G; Wong SC; Feldman DN
    J Invasive Cardiol; 2015 Nov; 27(11):490-6. PubMed ID: 25999136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
    Kaya A; Kurt M; Tanboğa IH; Işik T; Ekinci M; Aksakal E; Kaya Y; Topçu S; Sevimli S
    Acta Cardiol; 2013 Oct; 68(5):489-94. PubMed ID: 24283110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention.
    Liu Y; Liu YH; Tan N; Chen JY; Zhou YL; Li LW; Duan CY; Chen PY; Luo JF; Li HL; Wei-Guo
    PLoS One; 2014; 9(10):e111124. PubMed ID: 25357250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between rosuvastatin and atorvastatin for the prevention of contrast-induced nephropathy in patients with STEMI undergoing primary percutaneous coronary intervention.
    Firouzi A; Kazem Moussavi A; Mohebbi A; Alemzadeh-Ansari MJ; Kiani R; Sanati HR; Mohebbi B; Shakerian F; Zahedmehr A; Ansari-Ramandi MM; Oni Heris S; Ghaleshi B; Ghorbani F
    J Cardiovasc Thorac Res; 2018; 10(3):149-152. PubMed ID: 30386535
    [No Abstract]   [Full Text] [Related]  

  • 10. Association between N-terminal pro-brain natriuretic peptide levels and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Kurtul A; Duran M; Yarlioglues M; Murat SN; Demircelik MB; Ergun G; Acikgoz SK; Sensoy B; Cetin M; Ornek E
    Clin Cardiol; 2014 Aug; 37(8):485-92. PubMed ID: 24805995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Chronic Total Occlusion Versus Non-Occlusive Coronary Artery Disease.
    Demir OM; Lombardo F; Poletti E; Laricchia A; Beneduce A; Maccagni D; Slavich M; Giannini F; Carlino M; Margonato A; Cappelletti A; Colombo A; Azzalini L
    Am J Cardiol; 2018 Dec; 122(11):1837-1842. PubMed ID: 30292337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrast-Induced Nephropathy in STEMI Patients With and Without Chronic Kidney Disease.
    Jain T; Shah S; Shah J; Jacobsen G; Khandelwal A
    Crit Pathw Cardiol; 2018 Mar; 17(1):25-31. PubMed ID: 29432373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
    Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of High Dose Rosuvastatin Loading before Primary Percutaneous Coronary Intervention on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction.
    Kim JW; Yun KH; Kim EK; Kim YC; Joe DY; Ko JS; Rhee SJ; Lee EM; Yoo NJ; Kim NH; Oh SK; Jeong JW
    Korean Circ J; 2014 Mar; 44(2):76-81. PubMed ID: 24653736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.
    Yun KH; Jeong MH; Oh SK; Rhee SJ; Park EM; Lee EM; Yoo NJ; Kim NH; Ahn YK; Jeong JW
    Int J Cardiol; 2009 Nov; 137(3):246-51. PubMed ID: 18706705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Neutrophil-to-lymphocyte Ratio with Contrast-induced Nephropathy in Patients with Non-ST-elevation Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention.
    Kurtul A; Yarlioglues M; Duran M; Murat SN
    Heart Lung Circ; 2016 Jul; 25(7):683-90. PubMed ID: 26935164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI.
    Wickenbrock I; Perings C; Maagh P; Quack I; van Bracht M; Prull MW; Plehn G; Trappe HJ; Meissner A
    Clin Res Cardiol; 2009 Dec; 98(12):765-72. PubMed ID: 19851800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
    Wang Z; Dai H; Xing M; Yu Z; Lin X; Wang S; Zhang J; Hou F; Ma Y; Ren Y; Tan K; Wang Y; Ge Z
    J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):327-33. PubMed ID: 23364255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of combination therapy of statin and N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Park SH; Jeong MH; Park IH; Choi JS; Rhee JA; Kim IS; Kim MC; Cho JY; Sim DS; Hong YJ; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
    Int J Cardiol; 2016 Jun; 212():100-6. PubMed ID: 27045874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Kurtul A; Yarlioglues M; Murat SN; Demircelik MB; Acikgoz SK; Ergun G; Duran M; Cetin M; Ornek E
    Angiology; 2015 May; 66(5):433-40. PubMed ID: 24834929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.